創薬流通市場「薬市楽座」

安土桃山時代に自由取引市場として発展した「楽市楽座」にあやかり、創薬シーズ・技術のマーケットプラットフォームを創薬流通市場、「薬市楽座」と名付けました。このマーケットが楽市楽座のように発展することを願っています。

創薬流通市場である薬市楽座では、弊社がお預かりしている創薬シーズ・技術の情報をリストアップしています。ご興味に応じて検索していただくことが可能です。また、リストのダウンロードも行っていただけます。ご興味のあるものがあれば、お問い合わせボタンをクリックしていただき、弊社へのコンタクトをお願いいたします。追加情報を開示させていただきます。

なお、2019年6月27日より、日本語ページにおける、創薬シーズ、創薬技術の各リスト表記が英語に変更になりました。ダウンロード用のPDF、エクセルファイルは英語ページよりダウンロードできる資料と同一ですので、予めご了承下さいませ。

創薬シーズ・創薬技術一覧(PDF) 創薬シーズ・創薬技術一覧(Excel)

絞り込み検索

掲載日 シーズ番号 作用機序 適応症 投与経路 モダリティ 開発ステージ 備考
19/06/27 GEM082 Modified IL-1 receptor antagonist (IL-1RA) Refer to Note Intra-articular Protein
Preclinical Indication: Osteoarthritis, gout, anterior cruciate ligament (ACL) injury

Single intra-articular injection of Anakinra (rhIL-1RA) improved OA symptoms vs placebo in clinical Phase-2 but the effect was short-lasting.
GEM082 showed prolonged retention in the joint and sustained efficacy. GEM082 targets directly the biology of the inflammasome, involved in acute OA pain flares, without the adverse effects of steroids.
Avaliable for licensing to Japan, China and Taiwan.
問合せ
19/06/12 GEM081 Oncolytic virus Refer to Note IM Virus
Phase 2 ready Indication:
Solid tumor (Melanoma, GI cancer etc.)

Genetically non-modified and non-pathogenic virus with
- oncolytic, oncotropic and immunomodulating properties
- excellent safety profile
- various development options
Medicine containing this virus is already approved for treatment for many years in certain countries.
This virus has established fully GMP certified API production
問合せ
19/06/06 GEM080 Novel cell surface receptor for insoluble protein involved in Parkinson's/Lewy body diseases Parkinson's diseases, Lewy body disease NA NA
Preclinical Cell surface receptors for insoluble protein involved in Parkinson's disease/Lewy body disease which were newly identified by utilizing artificial liposomes embedded with endogenous membrane proteins (see TGEM025 in Technology). Antagonists of the receptors are expected to be effective on Parkinson's/Lewy body diseases. 問合せ
19/06/06 GEM079 Novel cell surface receptor for angiogenesis regulation Cancers, chronic inflammation, diabetic retinopathy , myocardial infarction, etc NA NA
Preclinical Cell surface receptor involved in angiogenesis which was newly identified by utilizing artificial liposomes embedded with endogenous membrane proteins (see TGEM025 in Technology). Agonists of the receptor are expected to be effective on diseases where angiogenesis is involved as an aggravating factor. 問合せ
19/05/30 GEM078 Hyaluronic acid-based nanocarriers of cisplatin Head and neck cancer, pancreatic cancer, melanoma with metastasis IV Small molecule
Preclinical CD44 targeting and higher stability lead to enhance lymphatic delivery and inhibit cancer with lymphatic metastasis.
Chemodrug encapsulated by nanocarriers minimize systemic toxicities.
Convenient dosing by intravenous injection.
問合せ
19/05/30 GEM077 AMPK activator Topical fat accumulation Transdermal or oral Small molecule
Preclinical A small molecular AMPK activator. It inhibited the growth of adipocytes in vitro and suppressed body weight and fat increases in vivo. Topical used formulation is under testing. 問合せ
19/05/30 GEM076 Galectin-12 inhibitor Seborrheic dermatitis; Sebaceous hyperplasia Transdermal siRNA
Preclinical A modified siRNA for suppressing gene expression of galectin-12 which is a lipid droplet protein and regulates lipid accumulation and lipolysis. The siRNA can reduce the lipid in sebocytes and adipocytes and shows good stability and selectivity to reduce the lipid accumulation through transdermal delivery in vivo. 問合せ
19/05/30 GEM075 Novel functional excipient Oral formulation* Oral Polymer
Preclinical The synthetic polyvinyl acetate (PVAc)-based polymer of functional excipient is utilized as solubilizer that could increase drug solubility and enhance drug absorption. This novel excipient has better flowability, easy for use and widely application. This excipient will be useful for new drug and insoluble drug development.

*: e.g. direct compression, granulation, solid dispersion
問合せ
19/05/30 GEM074 Dual inhibitor of Topo 1 and Topo 2 Drug resistant cancers IV Small molecule
Phase I 1st-in-class combo therapy, covalently conjugated to simultaneously inhibit Topo 1 and 2, w/ EGFR cross-talk and extremely low toxicity for high dosing.
Reduced tumor sizes w/ 38% CR and 98% TGI (compared to 0% and 33%, respectively, for imatinib) in CML xenograft models; and 98% TGI in colon cancer models at low doses. Showed immunotherapy enhancement effects with anti-PD-1 Ab and anti-CTLA-4 Ab with 100% CR in ovarian cancer model.
No toxicity in rat & monkey models; No SAEs reported in Phase I at high dose 180mg/m2. Excellent PK profile and GI permeability of 9.2 enabling oral formulation.
問合せ
19/05/30 GEM073 Kinase inhibitor of TGFβ-mediated phospho-SMAD2 signal transduction COPD, IPF, Lung cancer Oral Small molecule
Phase I ongoing This kinase is selectively expressed in resident macrophages and airways epithelia of the lung and upregulated in COPD and IPF patients.
A highly selective inhibitor showed efficacy across at least 3 different animal models relevant to COPD, IPF and NSCLC.
問合せ